Table 2.
Themes evaluated and retained for the Delphi survey
| Clinical domain for aripiprazole prescription: | |
|---|---|
| 1 | First episode psychosis |
| 2 | Acute exacerbation or relapse of psychosis |
| 3 | Agitation (intramuscular injection) |
| 4 | Long-term maintenance therapy |
| 5 | Onset of cardiovascular or metabolic disorders |
| 6 | Onset of hyperprolactinemia or sexual disorders |
| 7 | Occurrence of cognitive disorders |
| 8 | Secondary negative symptoms |
| 9 | Partial response (other than resistant schizophrenia) |
| 10 | Addictive comorbidity |
| 11 | Resistant schizophrenia in association with clozapine |
| 12 | Resistant schizophrenia as monotherapy |
| 13 | Resistant schizophrenia in association (without clozapine) |
| 14 | Pregnancy |
Themes in bold were those retained for the Delphi survey